A weekly live audience show featuring the people building and funding companies that are extending healthy human lifespan. Join us Thursdays on Clubhouse and check the show schedule on longevitybiotechshow.com
The Longevity Biotech Show was founded by Nathan Cheng (Longevity List, Longevity Marketcap) and Robert Ziman (Cohen Lab) in 2021. It originally started as a casual Clubhouse chat before morphing into a live audience podcast show.
All content for The Longevity Biotech Show is the property of The Longevity Biotech Show and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A weekly live audience show featuring the people building and funding companies that are extending healthy human lifespan. Join us Thursdays on Clubhouse and check the show schedule on longevitybiotechshow.com
The Longevity Biotech Show was founded by Nathan Cheng (Longevity List, Longevity Marketcap) and Robert Ziman (Cohen Lab) in 2021. It originally started as a casual Clubhouse chat before morphing into a live audience podcast show.
#012: Matthew Scholz (Oisin Biotechnologies) - May 6th, 2021
The Longevity Biotech Show
1 hour 14 minutes 36 seconds
4 years ago
#012: Matthew Scholz (Oisin Biotechnologies) - May 6th, 2021
Matthew Scholz is the co-founder of Oisin Biotechnologies, a gene therapy platform company that is targeting aging by killing senescent cells. We discuss the technology behind Oisin, Matt's journey from computer science to biotech, and practical advice and wisdom he gained from building biotech startups.
The Longevity Biotech Show
A weekly live audience show featuring the people building and funding companies that are extending healthy human lifespan. Join us Thursdays on Clubhouse and check the show schedule on longevitybiotechshow.com
The Longevity Biotech Show was founded by Nathan Cheng (Longevity List, Longevity Marketcap) and Robert Ziman (Cohen Lab) in 2021. It originally started as a casual Clubhouse chat before morphing into a live audience podcast show.
